COVID-19 Impact on Global Kidney Cancer Drug Market Size, Status and Forecast 2020-2026

September 2020 | 128 pages | ID: CDD240361839EN
QYResearch

Abstracts

This report focuses on the global Kidney Cancer Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Active Biotech
• Amgen
• Bayer AG
• Cipla Limited
• F. Hoffmann-La Roche
• Genentech
• Glaxosmithkline PLC
• Novartis AG
• Onyx Pharmaceuticals
• Pfizer
• Abbott Laboratories
• Aveo Pharmaceuticals
• Immatics Biotechnologies
• Prometheus Laboratories
• Exelixis

Market segment by Type, the product can be split into

• Nexavar (Sorafenib)
• Sutent (Sunitinib)
• Afinitor (Everolimus)
• Votrient (Pazopanib)
• Avastin (Bevacizumab)
• Inlyta (Axitinib)
• Torisel (Temsirolimus)
• Proleukin (Aldesleukin)
• Other

Market segment by Application, split into

• Hospitals
• Clinics
• Research Center
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Kidney Cancer Drug status, future forecast, growth opportunity, key market and key players.
• To present the Kidney Cancer Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Kidney Cancer Drug are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Kidney Cancer Drug Revenue
1.4 Market Analysis by Type
  1.4.1 Global Kidney Cancer Drug Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Nexavar (Sorafenib)
  1.4.3 Sutent (Sunitinib)
  1.4.4 Afinitor (Everolimus)
  1.4.5 Votrient (Pazopanib)
  1.4.6 Avastin (Bevacizumab)
  1.4.7 Inlyta (Axitinib)
  1.4.8 Torisel (Temsirolimus)
  1.4.9 Proleukin (Aldesleukin)
  1.4.10 Other
1.5 Market by Application
  1.5.1 Global Kidney Cancer Drug Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinics
  1.5.4 Research Center
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Kidney Cancer Drug Industry Impact
  1.6.1 How the Covid-19 is Affecting the Kidney Cancer Drug Industry
    1.6.1.1 Kidney Cancer Drug Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Kidney Cancer Drug Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Kidney Cancer Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Kidney Cancer Drug Market Perspective (2015-2026)
2.2 Kidney Cancer Drug Growth Trends by Regions
  2.2.1 Kidney Cancer Drug Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Kidney Cancer Drug Historic Market Share by Regions (2015-2020)
  2.2.3 Kidney Cancer Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Kidney Cancer Drug Market Growth Strategy
  2.3.6 Primary Interviews with Key Kidney Cancer Drug Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Kidney Cancer Drug Players by Market Size
  3.1.1 Global Top Kidney Cancer Drug Players by Revenue (2015-2020)
  3.1.2 Global Kidney Cancer Drug Revenue Market Share by Players (2015-2020)
  3.1.3 Global Kidney Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Kidney Cancer Drug Market Concentration Ratio
  3.2.1 Global Kidney Cancer Drug Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Kidney Cancer Drug Revenue in 2019
3.3 Kidney Cancer Drug Key Players Head office and Area Served
3.4 Key Players Kidney Cancer Drug Product Solution and Service
3.5 Date of Enter into Kidney Cancer Drug Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Kidney Cancer Drug Historic Market Size by Type (2015-2020)
4.2 Global Kidney Cancer Drug Forecasted Market Size by Type (2021-2026)

5 KIDNEY CANCER DRUG BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Kidney Cancer Drug Market Size by Application (2015-2020)
5.2 Global Kidney Cancer Drug Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Kidney Cancer Drug Market Size (2015-2020)
6.2 Kidney Cancer Drug Key Players in North America (2019-2020)
6.3 North America Kidney Cancer Drug Market Size by Type (2015-2020)
6.4 North America Kidney Cancer Drug Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Kidney Cancer Drug Market Size (2015-2020)
7.2 Kidney Cancer Drug Key Players in Europe (2019-2020)
7.3 Europe Kidney Cancer Drug Market Size by Type (2015-2020)
7.4 Europe Kidney Cancer Drug Market Size by Application (2015-2020)

8 CHINA

8.1 China Kidney Cancer Drug Market Size (2015-2020)
8.2 Kidney Cancer Drug Key Players in China (2019-2020)
8.3 China Kidney Cancer Drug Market Size by Type (2015-2020)
8.4 China Kidney Cancer Drug Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Kidney Cancer Drug Market Size (2015-2020)
9.2 Kidney Cancer Drug Key Players in Japan (2019-2020)
9.3 Japan Kidney Cancer Drug Market Size by Type (2015-2020)
9.4 Japan Kidney Cancer Drug Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Kidney Cancer Drug Market Size (2015-2020)
10.2 Kidney Cancer Drug Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Kidney Cancer Drug Market Size by Type (2015-2020)
10.4 Southeast Asia Kidney Cancer Drug Market Size by Application (2015-2020)

11 INDIA

11.1 India Kidney Cancer Drug Market Size (2015-2020)
11.2 Kidney Cancer Drug Key Players in India (2019-2020)
11.3 India Kidney Cancer Drug Market Size by Type (2015-2020)
11.4 India Kidney Cancer Drug Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Kidney Cancer Drug Market Size (2015-2020)
12.2 Kidney Cancer Drug Key Players in Central & South America (2019-2020)
12.3 Central & South America Kidney Cancer Drug Market Size by Type (2015-2020)
12.4 Central & South America Kidney Cancer Drug Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Active Biotech
  13.1.1 Active Biotech Company Details
  13.1.2 Active Biotech Business Overview and Its Total Revenue
  13.1.3 Active Biotech Kidney Cancer Drug Introduction
  13.1.4 Active Biotech Revenue in Kidney Cancer Drug Business (2015-2020))
  13.1.5 Active Biotech Recent Development
13.2 Amgen
  13.2.1 Amgen Company Details
  13.2.2 Amgen Business Overview and Its Total Revenue
  13.2.3 Amgen Kidney Cancer Drug Introduction
  13.2.4 Amgen Revenue in Kidney Cancer Drug Business (2015-2020)
  13.2.5 Amgen Recent Development
13.3 Bayer AG
  13.3.1 Bayer AG Company Details
  13.3.2 Bayer AG Business Overview and Its Total Revenue
  13.3.3 Bayer AG Kidney Cancer Drug Introduction
  13.3.4 Bayer AG Revenue in Kidney Cancer Drug Business (2015-2020)
  13.3.5 Bayer AG Recent Development
13.4 Cipla Limited
  13.4.1 Cipla Limited Company Details
  13.4.2 Cipla Limited Business Overview and Its Total Revenue
  13.4.3 Cipla Limited Kidney Cancer Drug Introduction
  13.4.4 Cipla Limited Revenue in Kidney Cancer Drug Business (2015-2020)
  13.4.5 Cipla Limited Recent Development
13.5 F. Hoffmann-La Roche
  13.5.1 F. Hoffmann-La Roche Company Details
  13.5.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
  13.5.3 F. Hoffmann-La Roche Kidney Cancer Drug Introduction
  13.5.4 F. Hoffmann-La Roche Revenue in Kidney Cancer Drug Business (2015-2020)
  13.5.5 F. Hoffmann-La Roche Recent Development
13.6 Genentech
  13.6.1 Genentech Company Details
  13.6.2 Genentech Business Overview and Its Total Revenue
  13.6.3 Genentech Kidney Cancer Drug Introduction
  13.6.4 Genentech Revenue in Kidney Cancer Drug Business (2015-2020)
  13.6.5 Genentech Recent Development
13.7 Glaxosmithkline PLC
  13.7.1 Glaxosmithkline PLC Company Details
  13.7.2 Glaxosmithkline PLC Business Overview and Its Total Revenue
  13.7.3 Glaxosmithkline PLC Kidney Cancer Drug Introduction
  13.7.4 Glaxosmithkline PLC Revenue in Kidney Cancer Drug Business (2015-2020)
  13.7.5 Glaxosmithkline PLC Recent Development
13.8 Novartis AG
  13.8.1 Novartis AG Company Details
  13.8.2 Novartis AG Business Overview and Its Total Revenue
  13.8.3 Novartis AG Kidney Cancer Drug Introduction
  13.8.4 Novartis AG Revenue in Kidney Cancer Drug Business (2015-2020)
  13.8.5 Novartis AG Recent Development
13.9 Onyx Pharmaceuticals
  13.9.1 Onyx Pharmaceuticals Company Details
  13.9.2 Onyx Pharmaceuticals Business Overview and Its Total Revenue
  13.9.3 Onyx Pharmaceuticals Kidney Cancer Drug Introduction
  13.9.4 Onyx Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
  13.9.5 Onyx Pharmaceuticals Recent Development
13.10 Pfizer
  13.10.1 Pfizer Company Details
  13.10.2 Pfizer Business Overview and Its Total Revenue
  13.10.3 Pfizer Kidney Cancer Drug Introduction
  13.10.4 Pfizer Revenue in Kidney Cancer Drug Business (2015-2020)
  13.10.5 Pfizer Recent Development
13.11 Abbott Laboratories
  10.11.1 Abbott Laboratories Company Details
  10.11.2 Abbott Laboratories Business Overview and Its Total Revenue
  10.11.3 Abbott Laboratories Kidney Cancer Drug Introduction
  10.11.4 Abbott Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
  10.11.5 Abbott Laboratories Recent Development
13.12 Aveo Pharmaceuticals
  10.12.1 Aveo Pharmaceuticals Company Details
  10.12.2 Aveo Pharmaceuticals Business Overview and Its Total Revenue
  10.12.3 Aveo Pharmaceuticals Kidney Cancer Drug Introduction
  10.12.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
  10.12.5 Aveo Pharmaceuticals Recent Development
13.13 Immatics Biotechnologies
  10.13.1 Immatics Biotechnologies Company Details
  10.13.2 Immatics Biotechnologies Business Overview and Its Total Revenue
  10.13.3 Immatics Biotechnologies Kidney Cancer Drug Introduction
  10.13.4 Immatics Biotechnologies Revenue in Kidney Cancer Drug Business (2015-2020)
  10.13.5 Immatics Biotechnologies Recent Development
13.14 Prometheus Laboratories
  10.14.1 Prometheus Laboratories Company Details
  10.14.2 Prometheus Laboratories Business Overview and Its Total Revenue
  10.14.3 Prometheus Laboratories Kidney Cancer Drug Introduction
  10.14.4 Prometheus Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
  10.14.5 Prometheus Laboratories Recent Development
13.15 Exelixis
  10.15.1 Exelixis Company Details
  10.15.2 Exelixis Business Overview and Its Total Revenue
  10.15.3 Exelixis Kidney Cancer Drug Introduction
  10.15.4 Exelixis Revenue in Kidney Cancer Drug Business (2015-2020)
  10.15.5 Exelixis Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Kidney Cancer Drug Key Market Segments
Table 2. Key Players Covered: Ranking by Kidney Cancer Drug Revenue
Table 3. Ranking of Global Top Kidney Cancer Drug Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Kidney Cancer Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Nexavar (Sorafenib)
Table 6. Key Players of Sutent (Sunitinib)
Table 7. Key Players of Afinitor (Everolimus)
Table 8. Key Players of Votrient (Pazopanib)
Table 9. Key Players of Avastin (Bevacizumab)
Table 10. Key Players of Inlyta (Axitinib)
Table 11. Key Players of Torisel (Temsirolimus)
Table 12. Key Players of Proleukin (Aldesleukin)
Table 13. Key Players of Other
Table 14. COVID-19 Impact Global Market: (Four Kidney Cancer Drug Market Size Forecast Scenarios)
Table 15. Opportunities and Trends for Kidney Cancer Drug Players in the COVID-19 Landscape
Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 17. Key Regions/Countries Measures against Covid-19 Impact
Table 18. Proposal for Kidney Cancer Drug Players to Combat Covid-19 Impact
Table 19. Global Kidney Cancer Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 20. Global Kidney Cancer Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 21. Global Kidney Cancer Drug Market Size by Regions (2015-2020) (US$ Million)
Table 22. Global Kidney Cancer Drug Market Share by Regions (2015-2020)
Table 23. Global Kidney Cancer Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 24. Global Kidney Cancer Drug Market Share by Regions (2021-2026)
Table 25. Market Top Trends
Table 26. Key Drivers: Impact Analysis
Table 27. Key Challenges
Table 28. Kidney Cancer Drug Market Growth Strategy
Table 29. Main Points Interviewed from Key Kidney Cancer Drug Players
Table 30. Global Kidney Cancer Drug Revenue by Players (2015-2020) (Million US$)
Table 31. Global Kidney Cancer Drug Market Share by Players (2015-2020)
Table 32. Global Top Kidney Cancer Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Drug as of 2019)
Table 33. Global Kidney Cancer Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 34. Key Players Headquarters and Area Served
Table 35. Key Players Kidney Cancer Drug Product Solution and Service
Table 36. Date of Enter into Kidney Cancer Drug Market
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 39. Global Kidney Cancer Drug Market Size Share by Type (2015-2020)
Table 40. Global Kidney Cancer Drug Revenue Market Share by Type (2021-2026)
Table 41. Global Kidney Cancer Drug Market Size Share by Application (2015-2020)
Table 42. Global Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 43. Global Kidney Cancer Drug Market Size Share by Application (2021-2026)
Table 44. North America Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 45. North America Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 46. North America Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 47. North America Kidney Cancer Drug Market Share by Type (2015-2020)
Table 48. North America Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 49. North America Kidney Cancer Drug Market Share by Application (2015-2020)
Table 50. Europe Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 51. Europe Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 52. Europe Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 53. Europe Kidney Cancer Drug Market Share by Type (2015-2020)
Table 54. Europe Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 55. Europe Kidney Cancer Drug Market Share by Application (2015-2020)
Table 56. China Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 57. China Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 58. China Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 59. China Kidney Cancer Drug Market Share by Type (2015-2020)
Table 60. China Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 61. China Kidney Cancer Drug Market Share by Application (2015-2020)
Table 62. Japan Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 63. Japan Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 64. Japan Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 65. Japan Kidney Cancer Drug Market Share by Type (2015-2020)
Table 66. Japan Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 67. Japan Kidney Cancer Drug Market Share by Application (2015-2020)
Table 68. Southeast Asia Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 69. Southeast Asia Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 70. Southeast Asia Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 71. Southeast Asia Kidney Cancer Drug Market Share by Type (2015-2020)
Table 72. Southeast Asia Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 73. Southeast Asia Kidney Cancer Drug Market Share by Application (2015-2020)
Table 74. India Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 75. India Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 76. India Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 77. India Kidney Cancer Drug Market Share by Type (2015-2020)
Table 78. India Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 79. India Kidney Cancer Drug Market Share by Application (2015-2020)
Table 80. Central & South America Key Players Kidney Cancer Drug Revenue (2019-2020) (Million US$)
Table 81. Central & South America Key Players Kidney Cancer Drug Market Share (2019-2020)
Table 82. Central & South America Kidney Cancer Drug Market Size by Type (2015-2020) (Million US$)
Table 83. Central & South America Kidney Cancer Drug Market Share by Type (2015-2020)
Table 84. Central & South America Kidney Cancer Drug Market Size by Application (2015-2020) (Million US$)
Table 85. Central & South America Kidney Cancer Drug Market Share by Application (2015-2020)
Table 86. Active Biotech Company Details
Table 87. Active Biotech Business Overview
Table 88. Active Biotech Product
Table 89. Active Biotech Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 90. Active Biotech Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Product
Table 94. Amgen Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 95. Amgen Recent Development
Table 96. Bayer AG Company Details
Table 97. Bayer AG Business Overview
Table 98. Bayer AG Product
Table 99. Bayer AG Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 100. Bayer AG Recent Development
Table 101. Cipla Limited Company Details
Table 102. Cipla Limited Business Overview
Table 103. Cipla Limited Product
Table 104. Cipla Limited Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 105. Cipla Limited Recent Development
Table 106. F. Hoffmann-La Roche Company Details
Table 107. F. Hoffmann-La Roche Business Overview
Table 108. F. Hoffmann-La Roche Product
Table 109. F. Hoffmann-La Roche Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 110. F. Hoffmann-La Roche Recent Development
Table 111. Genentech Company Details
Table 112. Genentech Business Overview
Table 113. Genentech Product
Table 114. Genentech Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 115. Genentech Recent Development
Table 116. Glaxosmithkline PLC Company Details
Table 117. Glaxosmithkline PLC Business Overview
Table 118. Glaxosmithkline PLC Product
Table 119. Glaxosmithkline PLC Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 120. Glaxosmithkline PLC Recent Development
Table 121. Novartis AG Business Overview
Table 122. Novartis AG Product
Table 123. Novartis AG Company Details
Table 124. Novartis AG Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 125. Novartis AG Recent Development
Table 126. Onyx Pharmaceuticals Company Details
Table 127. Onyx Pharmaceuticals Business Overview
Table 128. Onyx Pharmaceuticals Product
Table 129. Onyx Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 130. Onyx Pharmaceuticals Recent Development
Table 131. Pfizer Company Details
Table 132. Pfizer Business Overview
Table 133. Pfizer Product
Table 134. Pfizer Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 135. Pfizer Recent Development
Table 136. Abbott Laboratories Company Details
Table 137. Abbott Laboratories Business Overview
Table 138. Abbott Laboratories Product
Table 139. Abbott Laboratories Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 140. Abbott Laboratories Recent Development
Table 141. Aveo Pharmaceuticals Company Details
Table 142. Aveo Pharmaceuticals Business Overview
Table 143. Aveo Pharmaceuticals Product
Table 144. Aveo Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 145. Aveo Pharmaceuticals Recent Development
Table 146. Immatics Biotechnologies Company Details
Table 147. Immatics Biotechnologies Business Overview
Table 148. Immatics Biotechnologies Product
Table 149. Immatics Biotechnologies Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 150. Immatics Biotechnologies Recent Development
Table 151. Prometheus Laboratories Company Details
Table 152. Prometheus Laboratories Business Overview
Table 153. Prometheus Laboratories Product
Table 154. Prometheus Laboratories Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 155. Prometheus Laboratories Recent Development
Table 156. Exelixis Company Details
Table 157. Exelixis Business Overview
Table 158. Exelixis Product
Table 159. Exelixis Revenue in Kidney Cancer Drug Business (2015-2020) (Million US$)
Table 160. Exelixis Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Kidney Cancer Drug Market Share by Type: 2020 VS 2026
Figure 2. Nexavar (Sorafenib) Features
Figure 3. Sutent (Sunitinib) Features
Figure 4. Afinitor (Everolimus) Features
Figure 5. Votrient (Pazopanib) Features
Figure 6. Avastin (Bevacizumab) Features
Figure 7. Inlyta (Axitinib) Features
Figure 8. Torisel (Temsirolimus) Features
Figure 9. Proleukin (Aldesleukin) Features
Figure 10. Other Features
Figure 11. Global Kidney Cancer Drug Market Share by Application: 2020 VS 2026
Figure 12. Hospitals Case Studies
Figure 13. Clinics Case Studies
Figure 14. Research Center Case Studies
Figure 15. Other Case Studies
Figure 16. Kidney Cancer Drug Report Years Considered
Figure 17. Global Kidney Cancer Drug Market Size YoY Growth 2015-2026 (US$ Million)
Figure 18. Global Kidney Cancer Drug Market Share by Regions: 2020 VS 2026
Figure 19. Global Kidney Cancer Drug Market Share by Regions (2021-2026)
Figure 20. Porter's Five Forces Analysis
Figure 21. Global Kidney Cancer Drug Market Share by Players in 2019
Figure 22. Global Top Kidney Cancer Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Drug as of 2019
Figure 23. The Top 10 and 5 Players Market Share by Kidney Cancer Drug Revenue in 2019
Figure 24. North America Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Europe Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. China Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Japan Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Southeast Asia Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. India Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Central & South America Kidney Cancer Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Active Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Active Biotech Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 33. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Amgen Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 35. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Bayer AG Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 37. Cipla Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Cipla Limited Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 39. F. Hoffmann-La Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. F. Hoffmann-La Roche Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 41. Genentech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Genentech Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 43. Glaxosmithkline PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Glaxosmithkline PLC Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 45. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Novartis AG Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 47. Onyx Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Onyx Pharmaceuticals Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 49. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Pfizer Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 51. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Abbott Laboratories Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 53. Aveo Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Aveo Pharmaceuticals Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 55. Immatics Biotechnologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Immatics Biotechnologies Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 57. Prometheus Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Prometheus Laboratories Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 59. Exelixis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Exelixis Revenue Growth Rate in Kidney Cancer Drug Business (2015-2020)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed